iap0971
Recombinant proteinexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2022 (NCT05396391)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Payload
- il15
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06581419 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2024 | SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT06223841 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2024 | SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT06255964 | Phase 1/Phase 2 (Phase 2) | Feb 15, 2024 | Fudan University, SUNHO（China）BioPharmaceutical CO., Ltd. |
| NCT05396391 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2022 | SUNHO（China）BioPharmaceutical CO., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SUNHO（China）BioPharmaceutical CO., Ltd. | For profit | 4 | 4 | 1 | 2022 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1